Drug
Venanprubart clinical trials
Also written LY3361237.
- studies test it
- 5
- open now
- 0
- in phase 3
- 0
- first study started
- 2018
How studies write it
Studies that test it under each name
Studies by the year they started
5 studies that test it; most in 2018 (1)
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2019 | 1 |
| 2021 | 1 |
| 2022 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 4 · Other 1
Studies
Open first, then newest update. How each study uses venanprubart is read from its arms, and is right about nine times in ten.
Testing it · 5
- A IMMA Master Protocol: A Study of LY3361237 in Participants With at Least Moderately Active Systemic Lupus ErythematosusTerminatedPhase 2Eli Lilly and CompanyNCT05123586Written as LY3361237
- Anti-BTLA Agonist Therapy in Subjects With Primary Sjogren's SyndromeWithdrawnPhase 2Stanford UniversityNCT05781451Written as LY3361237
- A Study of LY3361237 in Participants With PsoriasisCompletedPhase 1Eli Lilly and CompanyNCT04975295Written as LY3361237
- A Study of LY3361237 in Participants With Systemic Lupus ErythematosusCompletedPhase 1Eli Lilly and CompanyNCT03933943Written as LY3361237
- A Study of LY3361237 in Healthy ParticipantsCompletedPhase 1Eli Lilly and CompanyNCT03695198Written as LY3361237 - SC
Codes
What other systems call venanprubart · ClinicalTrials.gg INT015832
- UNII (FDA) 9A1RH2QLX2VENANPRUBARTOne source FDA
- NCI Thesaurus C199128VenanprubartOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 9A1RH2QLX2 | VENANPRUBART | One source FDA |
| NCI Thesaurus | C199128 | Venanprubart | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.